Retatrutide · Pep IQ

Origin & Background

Beyond tirzepatide — the triple agonist

Retatrutide (LY3437943) is Eli Lilly's next-generation obesity drug — a single molecule that simultaneously activates all three key incretin hormone receptors: GLP-1, GIP, and glucagon. While tirzepatide (Mounjaro/Zepbound) combined GLP-1 and GIP to produce superior weight loss over semaglutide, retatrutide adds glucagon receptor agonism to the dual incretin platform. Glucagon is the "counter-regulatory" hormone normally seen as the opposite of insulin — but at the receptor level, glucagon agonism in this context increases energy expenditure, drives hepatic fat reduction, and reduces LDL cholesterol through PCSK9 degradation. This is the rationale for the triple combination.

The Phase 2 NEJM trial (2023, n=338, published simultaneously in NEJM) was the most impressive weight loss trial data ever published at that point: 24.2% mean body weight reduction at 48 weeks in the 12mg dose group versus 2.1% placebo. 72% of participants with prediabetes reverted to normoglycemia. 90%+ with NAFLD achieved liver fat normalisation at the highest dose. A parallel Nature Medicine (2024) substudy showed 82% reduction in liver fat.

December 11, 2025: Eli Lilly announced positive Phase 3 TRIUMPH-4 topline results — 28.7% weight loss at 68 weeks in adults with obesity and knee osteoarthritis, with significant reductions in joint pain. This is the first Phase 3 success for retatrutide. TRIUMPH-1, the pivotal obesity trial, followed in May 2026 (28.3% at 80 weeks on 12mg) — see below. Lilly's FDA submission is now planned for Q1 2027.

Why glucagon adds value: Glucagon's role extends far beyond blood sugar counter-regulation. Glucagon receptors in the liver drive hepatic fat oxidation and reduce triglycerides. Glucagon increases energy expenditure independently of appetite suppression. Glucagon agonism also degrades PCSK9 — reducing LDL cholesterol by approximately 20%. These are effects neither GLP-1 nor GIP provides. The triple combination is genuinely mechanistically additive, not merely pharmacologically redundant.

Science & Mechanism

Three receptors, one molecule

Mechanism of Action

GLP-1R activation: Central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion. The same foundational mechanism as semaglutide and tirzepatide's first component.

GIPR activation: Amplifies GLP-1 satiety signalling, acts on adipose tissue, enhances insulin secretion synergistically. Tirzepatide's second receptor — responsible for the step-change over semaglutide.

Glucagon receptor (GCGR) activation: The new addition. Increases hepatic fat oxidation and reduces liver fat (82% reduction in the NAFLD substudy). Increases overall energy expenditure — the "thermogenic" component absent from GLP-1 and GIP agonism. Degrades PCSK9, reducing LDL cholesterol ~20%.

Potency balance: Retatrutide is more potent at human GIP receptors than at GLP-1 or glucagon receptors — a deliberate design choice to maximise the additive satiety signalling while using glucagon's hepatic and thermogenic effects at doses that don't cause problematic hyperglycaemia.

Extended half-life: Like semaglutide and tirzepatide, retatrutide is engineered for once-weekly subcutaneous dosing. The long half-life is achieved through fatty acid side chains enabling albumin binding.

The Phase 2 data was remarkable across multiple outcomes. At the 12mg dose: 24.2% weight loss at 48 weeks; 100% of participants achieved ≥5% weight loss; 83% achieved ≥15% weight loss; 72% of prediabetics reverted to normoglycemia; and 90%+ with NAFLD normalised liver fat. The meta-analysis of Phase 2 RCTs (878 patients) confirmed mean weight reduction of 14.33% across all doses.

Phase 3 TRIUMPH-4 (December 2025): 28.7% mean weight loss at 68 weeks (12mg dose), with 26.4% at 9mg. Significant joint pain reduction (75.8% improvement in WOMAC pain score). LDL and triglycerides reduced. Systolic blood pressure reduced by 14mmHg at highest dose.

Phase 3 TRIUMPH-1 (topline 21 May 2026; detailed data at ADA, June 2026): the pivotal 80-week obesity trial in adults without diabetes. Mean weight loss 19.0% at 4mg, 25.9% at 9mg and 28.3% at 12mg vs 2.2% placebo; 45.3% of the 12mg arm lost ≥30% of body weight, and participants with baseline BMI ≥35 who continued into a blinded extension reached 30.3% at 104 weeks. Discontinuation for adverse events rose with dose. Lilly reported dysesthesia (abnormal skin sensation) as a distinct adverse event, mostly mild, with most affected participants continuing. Pep IQ note: the per-arm discontinuation and dysesthesia rates circulating online have not yet been verified against a peer-reviewed publication, so they are not reproduced here. TRANSCEND-T2D-1 (type 2 diabetes) reported positive topline results in March 2026; TRIUMPH-2 and TRIUMPH-3 are expected later in 2026.

Regulatory timing (July 2026): Lilly had listed retatrutide among submissions expected by the end of 2026, but now plans the FDA application for the first quarter of 2027, citing the need for additional manufacturing and quality-control data. Approval before late 2027 is therefore unlikely.

Benefits & Evidence

What the data shows

⚖️

Weight loss — record-breaking

Phase 2 (NEJM 2023): 24.2% at 48 weeks, 12mg. Phase 3 TRIUMPH-4 (Dec 2025): 28.7% at 68 weeks — the highest weight loss ever recorded for any drug in a Phase 3 trial. 100% of participants at highest dose achieved ≥5% weight loss; 83% achieved ≥15%.

● Strong — Phase 2 NEJM + Phase 3 TRIUMPH-4

🫁

Liver fat reduction (MASH/NAFLD)

Nature Medicine 2024 substudy: up to 82% reduction in liver fat at 48 weeks. 90%+ of patients with NAFLD normalised liver fat content. Glucagon agonism drives hepatic fat oxidation through mechanisms independent of weight loss. Potential first pharmacological MASH treatment if approved.

● Strong — Phase 2 substudy · Nature Medicine

🩸

Glycaemic control

Phase 2 T2D trial: 16.9% weight loss at 36 weeks; HbA1c improved 2.2%; 82% reached HbA1c ≤6.5%; 77-82% achieved normoglycemia. Superior to dulaglutide 1.5mg. 72% of prediabetic obesity patients reverted to normoglycemia in the Phase 2 obesity trial.

● Strong — Phase 2 RCT data

🫀

Cardiovascular risk factors

LDL reduced ~20% (PCSK9 mechanism unique to glucagon component). Triglycerides reduced significantly. Systolic blood pressure −14mmHg. hsCRP reduced. Non-HDL cholesterol reduced. Phase 3 TRIUMPH-CV cardiovascular outcomes trial underway — results expected 2026-2027.

● Moderate — risk factors · MACE outcomes pending

🦵

Osteoarthritis pain (TRIUMPH-4)

TRIUMPH-4 (Phase 3): 75.8% improvement in WOMAC pain score alongside 28.7% weight loss in patients with obesity and knee OA. 14.1% of patients on 9mg were completely free of knee pain vs 4.2% placebo. Weight loss explains part of this; direct anti-inflammatory mechanisms may also contribute.

● Strong — Phase 3 RCT

Things to know

Risks & considerations

Moderate

GI side effects — nausea, diarrhoea, vomiting, constipation. Dose-related, predominantly during escalation. Higher rates than semaglutide or tirzepatide at equivalent phases, commensurate with greater efficacy.

Moderate

Muscle mass loss — as with all GLP-1 class drugs, 25–40% of weight lost without resistance training can be lean mass. The greater weight loss magnitude makes this risk proportionally higher than with semaglutide or tirzepatide.

Moderate

Higher discontinuation rate — 12–18% at high doses in Phase 3 vs 4% placebo. CITI analysts noted this correlates with higher baseline BMI and the rate of weight loss — not an unexpected finding for the most potent drug in the class.

Serious

Same class contraindications as GLP-1 agonists — thyroid C-cell tumour black box warning, pancreatitis risk, contraindicated in pregnancy and MEN-2/medullary thyroid cancer history.

⚠ Key Warnings

Retatrutide is NOT approved — it is an investigational drug in Phase 3 trials. It should not be used outside clinical trials. It is not available through compounding pharmacies or grey market sources (any product claiming to be retatrutide from unregulated sources cannot be verified).

FDA submission planned Q1 2027 (Lilly, July 2026); approval 2027–28 at the earliest. No approved retatrutide product exists anywhere. Grey-market supply drew MHRA investigations and a sharp rise in US poison-centre exposures in 2026. Do not attempt to source pre-approval.

If approved, the same resistance training + protein protocol essential for semaglutide and tirzepatide applies — with even greater urgency given the magnitude of weight loss.

Seven additional Phase 3 readouts expected in 2026, including cardiovascular outcomes. The full safety and efficacy profile will not be known until these complete.